| Maia Regina Nofal, | |
|
72 E Concord St Bldg C515, Boston, MA 02118-2642 | |
| (617) 638-8442 | |
| Not Available |
| Full Name | Maia Regina Nofal |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | 72 E Concord St Bldg C515, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083241798 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 285388 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Maia Regina Nofal, 72 E Concord St Bldg C515, Boston, MA 02118-2642 Ph: (617) 638-8442 | Maia Regina Nofal, 72 E Concord St Bldg C515, Boston, MA 02118-2642 Ph: (617) 638-8442 |
News Archive
Researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) have found a protein in the blood of pregnant women that can predict if they are likely to have a fetus that doesn't grow properly, and thus has a high risk of stillbirth and long-term health complications.
A team of international scientists has recently investigated the efficacy of PVP-1, a complex of polyvinylpyrrolidone and iodine, in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Using in vitro cell culture settings, the scientists observe that PVP-1 formulation used in a commercially available nasal spray (Nasodine) readily inactivates SARS-CoV-2 within a short period of time.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
Researchers at the University of South Australia have made a major discovery using a natural compound in snake venom that shows very promising anti-cancer effects. The compound works by activating the destruction of cells which make up the blood vessels that supply nutrients to tumours, according to Associate Professor Tony Woods from UniSA's School of Pharmaceutical, Molecular and Biomedical Sciences.
Quanterix announced that it will release its financial results for second quarter 2019 before the start of trading on Tuesday, Aug. 6, 2019.
› Verified 8 days ago
Hugh G Auchincloss, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2000 | |
Nicole J Look-hong, MD, MSC Surgery Medicare: Medicare Enrolled Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-724-3868 | |
Dr. Paul Jansson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Neville House 236a, Boston, MA 02115 Phone: 617-732-5500 | |
Vanessa Mercedes Welten, MD MPH Surgery Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. Joanna Wolf Etra, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Francis St Ste 9b, Boston, MA 02215 Phone: 617-632-9513 | |
Jennine Putnick, MD Surgery Medicare: Medicare Enrolled Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-632-9511 | |
Michael Tarnoff, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 800 Washington St, Nemc Box 7105, Boston, MA 02111 Phone: 617-636-5000 |